- Home
- IMCR vs ATEN Comparison
IMCR vs ATEN Comparison
Compare IMCR & ATEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IMCR
- ATEN
- Stock Information
- Founded
- IMCR 2008
- ATEN 2004
- Country
- IMCR United Kingdom
- ATEN United States
- Employees
- IMCR N/A
- ATEN N/A
- Industry
- IMCR Biotechnology: Biological Products (No Diagnostic Substances)
- ATEN EDP Services
- Sector
- IMCR Health Care
- ATEN Technology
- Exchange
- IMCR Nasdaq
- ATEN Nasdaq
- Market Cap
- IMCR 1.7B
- ATEN 1.4B
- IPO Year
- IMCR 2021
- ATEN 2014
- Fundamental
- Price
- IMCR $35.17
- ATEN $18.58
- Analyst Decision
- IMCR Buy
- ATEN Strong Buy
- Analyst Count
- IMCR 10
- ATEN 3
- Target Price
- IMCR $58.13
- ATEN $21.33
- AVG Volume (30 Days)
- IMCR 250.5K
- ATEN 902.5K
- Earning Date
- IMCR 08-07-2025
- ATEN 08-05-2025
- Dividend Yield
- IMCR N/A
- ATEN 1.29%
- EPS Growth
- IMCR N/A
- ATEN 9.85
- EPS
- IMCR N/A
- ATEN 0.67
- Revenue
- IMCR $333,581,000.00
- ATEN $267,158,000.00
- Revenue This Year
- IMCR $26.82
- ATEN $9.56
- Revenue Next Year
- IMCR $8.15
- ATEN $7.54
- P/E Ratio
- IMCR N/A
- ATEN $27.73
- Revenue Growth
- IMCR 25.75
- ATEN 4.90
- 52 Week Low
- IMCR $23.15
- ATEN $12.27
- 52 Week High
- IMCR $40.88
- ATEN $21.90
- Technical
- Relative Strength Index (RSI)
- IMCR 53.52
- ATEN 49.65
- Support Level
- IMCR $32.20
- ATEN $18.67
- Resistance Level
- IMCR $37.63
- ATEN $19.02
- Average True Range (ATR)
- IMCR 1.21
- ATEN 0.47
- MACD
- IMCR 0.03
- ATEN -0.06
- Stochastic Oscillator
- IMCR 53.90
- ATEN 53.58
About IMCR Immunocore Holdings plc
Immunocore Holdings PLC is a commercial-stage biotechnology company. Using its ImmTAX platform, the company is developing a deep pipeline in multiple therapeutic areas, including clinical stage programs in oncology and infectious disease, pre-clinical programs in autoimmune disease, and earlier pre-clinical programs across three therapeutic areas. The company's main product, KIMMTRAK, is used for the treatment of unresectable or metastatic uveal melanoma (mUM). The other drug candidates in its pipeline include Brenetafusp, IMC-P115C, IMC-T119C, IMC-R117C, IMC-S118AI, IMC-U120AI, and others, being developed as a potential treatment for various oncology, infectious, and autoimmune diseases.
About ATEN A10 Networks Inc.
A10 Networks Inc is a provider of security and infrastructure solutions for on-premises, hybrid cloud, and edge-cloud environments of its multinational enterprise, communication, cloud and web service provider customers who strive to provide business-critical applications and networks that are secure, available, and efficient. As cyber-attacks increase in volume and complexity, the company integrates security and artificial intelligence (AI) enabled capabilities in its solutions that enable its customers to continue to adapt to market trends in hybrid cloud, AI-ready data centers and the ever-increasing need for high-performance, high availability and low latency. The company generates the maximum of its revenue from Americas.